Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

DOI: https://doi.org/10.1182/blood-2022-158656

Published: 2022

Journal Articles

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Mohammad Alhomoud, Usama Gergis, Adrienne A. Phillips, Jingmei Hsu, Zhengming Chen, Alexandra Gomez-Arteaga, Tsiporah B. Shore, Joseph Scandura, Koen Van Besien, Sebastian A. Mayer

Blood (2022) 140 (Supplement 1): 7583–7584.

DOI: https://doi.org/10.1182/blood-2022-170097

Published: 2022

Journal Articles

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Blood (2022) 140 (Supplement 1): 3666–3668.

DOI: https://doi.org/10.1182/blood-2022-164988

Published: 2022

Journal Articles

Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2 + diffuse large B-cell lymphomas

Yajie Shen, Jingqi Zhou, Kui Nie, Shuhua Cheng, Zhengming Chen, Wenhan Wang, Weiqing Wei, Daiji Jiang, Zijing Peng, Yizhuo Ren, Yirong Zhang, Qiuju Fan, Kristy L. Richards, Yitao Qi, Jinke Cheng, Wayne Tam, Jiao Ma

Blood (2022) 139 (1): 73–86.

DOI: https://doi.org/10.1182/blood.2021012327

Published: 2022

Includes: Supplemental data

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

DOI: https://doi.org/10.1182/blood-2021-145495

Published: 2021

Journal Articles

Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant

Mateo Mejia Saldarriaga, Yassine Tahri, Sangmin Lee, Zhengming Chen, Tsiporah B. Shore, Danielle Guarneri, Sebastian A. Mayer, Adrienne A. Phillips, Alexandra Gomez-Arteaga, Pinkal Desai, Ellen Ritchie, Michael B. Samuel, Gail J. Roboz, Koen van Besien, Jingmei Hsu

Blood (2021) 138 (Supplement 1): 4833.

DOI: https://doi.org/10.1182/blood-2021-149297

Published: 2021

Journal Articles

FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma

Ja-Young Jang, Inah Hwang, Heng Pan, Michael Kluk, Jun Yao, Xiangao Huang, Maurizio Di Liberto, Zhengming Chen, Karla V Ballman, Lewis C Cantley, Giorgio Inghirami, Olivier Elemento, Robert Baiocchi, Selina Chen-Kiang, Sandro Belvedere, Hongwu Zheng, Jihye Paik

Blood (2021) 138 (Supplement 1): 30.

DOI: https://doi.org/10.1182/blood-2021-153378

Published: 2021

Journal Articles

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Kimihito C. Kawabata, Hongliang Zong, Cem Meydan, Sarah Wyman, Bas J. Wouters, Mayumi Sugita, Srinjoy Goswami, Michael Albert, Winnie Yip, Gail J. Roboz, Zhengming Chen, Ruud Delwel, Martin Carroll, Christopher E. Mason, Ari Melnick, Monica L. Guzman

Blood (2021) 137 (6): 812–825.

DOI: https://doi.org/10.1182/blood.2019001745

Published: 2021

Includes: Supplemental data

Journal Articles

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, MD PhD, Alison J. Moskowitz, MD, Neha Mehta-Shah, MD, Lubomir Sokol, MD PhD, Zhengming Chen, PhD MPH, MS, Riyaad Rahim, Wei Song, Koen Van Besien, MD PhD, Steven M. Horwitz, MD, Sarah C. Rutherford, MD, Morton Coleman, MD FACP, Ari Melnick, MD, Giorgio Inghirami, MD, Leandro Cerchietti, MD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 33–34.

DOI: https://doi.org/10.1182/blood-2020-136023

Published: 2020

Journal Articles

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

Prashasti Agrawal, Kevin A. David, MD, Zhengming Chen, PhD MPH, MS, Suchitra Sundaram, MD, Seo-Hyun Kim, MD, Ryan Vaca, MD, Yong Lin, PhD, Samuel Singer, MD, Mary-Kate Malecek, MD, Jordan Carter, MD, Adam Zayac, MD, Myung Sun Kim, MD, Nishitha Reddy, MD, Alma Habib, MD, Christopher Strouse, MD, Jerome Graber, MD, Veronika Bachanova, MD PhD, Mazie Tsang, MD, Ajay Major, MDMBA, David A. Bond, MD, Angel Mier-Hicks, MD, Pallawi Torka, MD, Priya Rajakumar, MD, Parameswaran Venugopal, MD, Michael Glantz, MD PhD, Samuel Goldlust, MD, Rahul Matnani, MD, Pallavi Kumar, MD, Thomas A Ollila, MD, Johnny Cai, DO, Stephen E. Spurgeon, MD, Alex G Sieg, MD MS, Joseph Cleveland, MD, Narendranath Epperla, MDMS, Reem Karmali, MDMSc, Seema Naik, MD, Sonali M. Smith, MD, James L. Rubenstein, MD PhD, Brad S. Kahl, MD, Amy Chadburn, MD, Andrew M. Evens, DO,MMSc, Peter Martin, FRCPC, MD MS

Blood (2020) 136 (Supplement 1): 4–6.

DOI: https://doi.org/10.1182/blood-2020-138885

Published: 2020

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

DOI: https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Yun Li, MD PhD, Meng Wu, MD, Huiqiang Huang, MD PhD, Wei Xu, MD PhD, Haiwen Huang, MD PhD, Weili Zhao, MD PhD, Yanyan Wang, MD, Shuo Liu, MD, Pengpeng Xu, MD, Zhengming Chen, Yuqin Song, MD PhD, Jia Ruan, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 3994.

DOI: https://doi.org/10.1182/blood-2019-125192

Published: 2019

Journal Articles

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Peter Martin, Nancy L. Bartlett, Kristie A. Blum, Steven Park, Kami Maddocks, Jia Ruan, LeAnn Ridling, Christopher Dittus, Zhengming Chen, Xiangao Huang, Giorgio Inghirami, Maurizio DiLiberto, Selina Chen-Kiang, John P. Leonard

Blood (2019) 133 (11): 1201–1204.

DOI: https://doi.org/10.1182/blood-2018-11-886457

Published: 2019

Journal Articles

Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma

Madhav Seshadri, MD, Zhengming Chen, PhD MPH, MS, Peter Martin, FRCPC, MD MS, John P. Leonard, MD, Tsiporah B. Shore, MD, Adrienne A. Phillips, MD MPH, Usama Gergis, MD M.B.A, Sarah C. Rutherford, John N. Allan, MD, Richard R. Furman, MD, Kristy Richards, MD PhD, Jingmei Hsu, MD, Sebastian A. Mayer, MD, Arcania Garcia, Channy Kong, Giorgio Inghirami, MD, Koen Van Besien, MD PhD, Jia Ruan, MD PhD

Blood (2018) 132 (Supplement 1): 1640.

DOI: https://doi.org/10.1182/blood-2018-99-111476

Published: 2018

Journal Articles

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Sangmin Lee, MD, Jingmei Hsu, MD, Yassine Tahri, MD, Zhengming Chen, PhD MPH, MS, Tsiporah B. Shore, MD, Ellen K. Ritchie, MD, Usama Gergis, MD M.B.A, Pinkal Desai, MD MPH, Sebastian A. Mayer, MD, Michael Samuel, MD, Adrienne A. Phillips, MD MPH, Melissa M. Cushing, MD, Gail J. Roboz, MD, Koen Van Besien, MD PhD

Blood (2018) 132 (Supplement 1): 2172.

DOI: https://doi.org/10.1182/blood-2018-99-119946

Published: 2018

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

DOI: https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Blood (2015) 126 (23): 3961.

DOI: https://doi.org/10.1182/blood.V126.23.3961.3961

Published: 2015

Journal Articles

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Xiangao Huang, PhD, David Jayabalan, BSMS, MSc, Maurizio Di Liberto, PhD, Zhengming Chen, PhD, Anna C Schinzel, PhD, Scott Ely, MD MPH, Adriana C Rossi, MD MHS, Roger N Pearse, MD PhD, Ekta Aneja, MBBS, Morton Coleman, MD, Joseph M Lane, MD, William C. Hahn, MD PhD, Tomer M Mark, MD MSc, Ruben Niesvizky, MD, Selina Chen-Kiang, PhD

Blood (2015) 126 (23): 500.

DOI: https://doi.org/10.1182/blood.V126.23.500.500

Published: 2015

NARROW

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Epigenetic Priming with 5-Azacytidine Prior to Allogeneic Stem Cell Transplantation for Myeloid Malignancies with In Vivo T Cell Depletion: Results of a Phase II Trial

Patterns of Care and Clinical Outcomes in Peripheral T-Cell Lymphomas: The Lymphoma Epidemiology of Outcomes (LEO) and Molecular Epidemiology Resource (LEO-MER) Prospective Cohort Study

Oncogenic role of the SOX9-DHCR24-cholesterol biosynthesis axis in IGH-BCL2 + diffuse large B-cell lymphomas

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Impact of Peri-Transplant Molecular Mutations on Outcomes of AML Patients Undergoing Fludarabine/Melphalan Conditioned Allogeneic Stem Cell Transplant

FOXO1 Dependent Transcription Network Is a Targetable Vulnerability of Mantle Cell Lymphoma

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells

Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)

EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma

Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Postibrutinib outcomes in patients with mantle cell lymphoma

Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

Inhibition of CDK4/CDK6 Sensitizes Myeloma to IMiD By Reducing the MEIS2 to Cereblon Ratio That Accelerates IKZF1 and IKZF3 Degradation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only